Dabigatran etexilate for venous thromboembolism: a safety evaluation

Bibliography

• DeCaterina R, Husted S, Wallentin L, et al.; European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Parenteral anticoagulants in heart disease: current status and perspectives (section II). Position paper of the ESC working Group on thrombosis-task Force on anticoagulants in heart disease. Thromb Haemost 2013;109:769–86
   PubMed Web of Science ®Google Scholar
• De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (section III). Position paper of the ESC working group on thrombosis - task force on anticoagulants in heart disease. Thromb Haemost 2013;110:1087-107
   PubMed Web of Science ®Google Scholar
• De Caterina R, Husted S, Wallentin L, et al.; European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. General mechanisms of coagulation and targets of anticoagulants (section I). Position paper of the ESC working group on thrombosis--task force on anticoagulants in heart disease. Thromb Haemost 2013;109:569-79
   PubMed Web of Science ®Google Scholar
• Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 2013;52:69-82
   PubMed Web of Science ®Google Scholar
• Begg EJ, Helsby NA, Jensen BP. Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis. Pharmacogenomics 2012;13:83-9
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99
   PubMed Web of Science ®Google Scholar
• Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol 2012;26:27-32
   PubMed Web of Science ®Google Scholar
• Huisman MV, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012;107:838-47
   PubMed Web of Science ®Google Scholar
• Turpie AG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor. Thromb Haemost 2012;108:876-86
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Dabigatran etexilate - a new oral thrombin inhibitor. Circulation 2011;123:1436-50
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Huo MH, et al.; RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011;105:721-9
   PubMed Web of Science ®Google Scholar
• Barnett D, Black DW, Buckley B, et al. (NICE Guideline Committee). Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement. surgery in adults. NICE technology appraisals TA157 2008
   Google Scholar
• Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-68
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar A, et al.; for the RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52
   PubMed Web of Science ®Google Scholar
• Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global geographic region on time in therapeutic Range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2013;2:e000067
   PubMed Web of Science ®Google Scholar
• Wieloch M, Själander A, Frykman V, et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thromboembolic complications from the national quality registry AuriculA. Eur Heart J 2011;32:2282
   PubMed Web of Science ®Google Scholar
• Schulman S, Kakkar AK, Schellong SM, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis (RE-COVER II). Circulation 2014;129(7):764-72
   PubMed Web of Science ®Google Scholar
• Fox BD, Kahn SR, Langleben et al. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012;345:e7498
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar A, et al.; for the RE-MEDY and the RE-SONATE Trials Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709-18
   PubMed Web of Science ®Google Scholar
• Adam J, Edes AE, Braybrooke J, et al. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. NICE technology appraisals TA261 2012
   Google Scholar
• Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009;101:77-85
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Healey JS, Eikelboom J, Douketis J, et al. RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 2012;126:343-8
   PubMed Web of Science ®Google Scholar
• Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61:2264-73
   PubMed Web of Science ®Google Scholar
• Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012;110:453-60
   PubMed Web of Science ®Google Scholar
• Eisert WG, Hauel N, Stangier J, et al. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010;30:1885-9
   PubMed Web of Science ®Google Scholar
• Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397-402
   PubMed Web of Science ®Google Scholar
• Clemens A, Fraessdorf M, Friedman J. Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag 2013;9:599-615
   PubMedGoogle Scholar
• Lip GY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 2010;123:785-9
   PubMed Web of Science ®Google Scholar
• Diener HC, Executive Steering Committee of the SPORTIF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006;21:279-93
   PubMed Web of Science ®Google Scholar
• Harper P. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012;366:864-6
   PubMed Web of Science ®Google Scholar
• Simon LS. Pharmacovigilance: towards a better understanding of the benefit to risk ratio. Ann Rheum Dis 2002;61(Suppl 2):ii88-9
   PubMedGoogle Scholar
• Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000829/WC500041059.pdf
   Google Scholar
• Gandhi PK, Gentry WM, Bottorff MB. Dabigatran-dronedarone interaction in a spontaneous reporting system. J Am Pharm Assoc (2003) 2013;53:414-19
   PubMed Web of Science ®Google Scholar
• Naccarelli GV, Wolbrette DL, Levin V, et al. Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter. Clin Med Insights Cardiol 2011;5:103-19
   PubMedGoogle Scholar
• Lapidus LJ, Ponzer S, Pettersson H, de Bri E. Symptomatic venous thromboembolism and mortality in orthopaedic surgery -- an observational study of 45 968 consecutive procedures. BMC Musculoskelet Disord 2013;14:177
   PubMedGoogle Scholar
• White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525-31
   PubMed Web of Science ®Google Scholar
• Picker SM, Gathof BS. [Heparin induced thrombocy topenia. A frequently unrecognised complication after major orthopedic surgery]. Orthopade 2004;33:1300-8
   PubMed Web of Science ®Google Scholar
• Warwick D. Prevention of venous thromboembolism in total knee and hip replacement. Circulation 2012;125:2151-5
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Brueckmann M, et al. for the RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-14
   PubMed Web of Science ®Google Scholar
• Sharrock NE, Della Valle AG, Go G, et al. Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee. Clin Orthop Relat Res 2008;466:714-21
   PubMed Web of Science ®Google Scholar
• O'Donnell M, Weitz JI. Thromboprophylaxis in surgical patients. Can J Surg 2003;46:129-35
   PubMed Web of Science ®Google Scholar
• Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011;106(5):968-77
   PubMed Web of Science ®Google Scholar
• Gallego P, Roldan V, Marín F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013;110(6):1189-98
   PubMed Web of Science ®Google Scholar
• Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: the treat randomised trial. PLoS One 2013;8(9):e74037
   PubMed Web of Science ®Google Scholar
• Veen LV, van Raay JJ, Gerritsma-Bleeker CL, et al. Direct treatment comparison of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA). BMJ Open 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Ostadal P, Alan D, Vejvoda J, et al. Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome. Exp Clin Cardiol 2008;13:175-8
   PubMedGoogle Scholar
• Simonneau G, Laporte S, Mismetti P, et al. FX140 Study Investigators. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost 2006;4:1693-700
   PubMed Web of Science ®Google Scholar